View ValuationOncoTherapy Science 将来の成長Future 基準チェック /06現在、 OncoTherapy Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長38.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).New Risk • Jan 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥7.91b market cap, or US$49.9m).分析記事 • Jan 08We're Hopeful That OncoTherapy Science (TSE:4564) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.11b market cap, or US$45.3m).Reported Earnings • Nov 09Second quarter 2026 earnings released: JP¥0.78 loss per share (vs JP¥0.91 loss in 2Q 2025)Second quarter 2026 results: JP¥0.78 loss per share (improved from JP¥0.91 loss in 2Q 2025). Revenue: JP¥230.0m (up 84% from 2Q 2025). Net loss: JP¥241.0m (flat on 2Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025分析記事 • Sep 24Here's Why We're Not Too Worried About OncoTherapy Science's (TSE:4564) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Aug 10First quarter 2026 earnings released: JP¥1.13 loss per share (vs JP¥1.30 loss in 1Q 2025)First quarter 2026 results: JP¥1.13 loss per share. Revenue: JP¥201.0m (up 101% from 1Q 2025). Net loss: JP¥314.0m (loss widened 4.0% from 1Q 2025).お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025Reported Earnings • Jun 29Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.New Risk • Jun 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥6.62b market cap, or US$45.6m).New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risk Market cap is less than US$100m (JP¥5.79b market cap, or US$40.3m).Reported Earnings • May 11Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.お知らせ • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.お知らせ • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.Reported Earnings • Feb 08Third quarter 2025 earnings released: JP¥0.63 loss per share (vs JP¥1.27 loss in 3Q 2024)Third quarter 2025 results: JP¥0.63 loss per share (improved from JP¥1.27 loss in 3Q 2024). Revenue: JP¥338.0m (up 207% from 3Q 2024). Net loss: JP¥172.0m (loss narrowed 38% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025分析記事 • Jan 29We're Keeping An Eye On OncoTherapy Science's (TSE:4564) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024分析記事 • Oct 11Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥9.81b market cap, or US$69.7m).New Risk • Aug 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥562m revenue, or US$3.8m). Market cap is less than US$100m (JP¥12.9b market cap, or US$87.8m).Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024お知らせ • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.分析記事 • Mar 01We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (JP¥8.68b market cap, or US$60.6m).Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 07Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 24Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Dec 07New 90-day low: JP¥124The company is down 2.0% from its price of JP¥126 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、OncoTherapy Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4564 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026808-910-984-922N/A12/31/2025784-881N/AN/AN/A9/30/2025956-825-822-762N/A6/30/2025851-827N/AN/AN/A3/31/2025750-815-815-815N/A12/31/2024707-1,018N/AN/AN/A9/30/2024479-1,123-926-926N/A6/30/2024562-1,190N/AN/AN/A3/31/2024610-1,288-1,229-1,227N/A12/31/2023901-1,192N/AN/AN/A9/30/2023976-1,215-1,163-1,157N/A6/30/2023897-1,241N/AN/AN/A3/31/20231,134-1,118-798-794N/A12/31/20221,517-1,345N/AN/AN/A9/30/20221,427-1,955-1,999-1,556N/A6/30/20221,445-2,314N/AN/AN/A3/31/20221,153-2,571-2,529-2,073N/A12/31/2021507-2,518N/AN/AN/A9/30/2021472-2,034-1,870-1,827N/A6/30/2021384-1,777N/AN/AN/A3/31/2021332-1,561-1,805-1,762N/A12/31/2020315-1,645N/AN/AN/A9/30/2020312-1,738-1,982-1,962N/A6/30/2020302-1,911N/AN/AN/A3/31/2020316-2,238-2,405-2,275N/A12/31/2019194-2,815N/AN/AN/A9/30/2019360-2,648N/A-2,321N/A6/30/2019322-2,932N/AN/AN/A3/31/2019280-2,934N/A-2,373N/A12/31/2018255-2,599N/AN/AN/A9/30/201834-3,026N/A-2,870N/A6/30/201824-2,930N/AN/AN/A3/31/2018211-2,851N/A-3,035N/A12/31/2017255-2,949N/AN/AN/A9/30/2017453-2,872N/A-2,839N/A6/30/2017486-2,806N/AN/AN/A3/31/2017286-3,002N/A-2,988N/A12/31/2016290-2,864N/AN/AN/A9/30/201692-2,951N/A-2,970N/A6/30/201660-3,012N/AN/AN/A3/31/2016266-2,788N/A-2,898N/A12/31/2015581-2,464N/AN/AN/A9/30/2015626-1,921N/A-2,455N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4564の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4564の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4564の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4564の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4564の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4564の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/11 23:35終値2026/07/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋OncoTherapy Science, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.
Reported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).
お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.
分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).
Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).
New Risk • Jan 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥7.91b market cap, or US$49.9m).
分析記事 • Jan 08We're Hopeful That OncoTherapy Science (TSE:4564) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.11b market cap, or US$45.3m).
Reported Earnings • Nov 09Second quarter 2026 earnings released: JP¥0.78 loss per share (vs JP¥0.91 loss in 2Q 2025)Second quarter 2026 results: JP¥0.78 loss per share (improved from JP¥0.91 loss in 2Q 2025). Revenue: JP¥230.0m (up 84% from 2Q 2025). Net loss: JP¥241.0m (flat on 2Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025
分析記事 • Sep 24Here's Why We're Not Too Worried About OncoTherapy Science's (TSE:4564) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Aug 10First quarter 2026 earnings released: JP¥1.13 loss per share (vs JP¥1.30 loss in 1Q 2025)First quarter 2026 results: JP¥1.13 loss per share. Revenue: JP¥201.0m (up 101% from 1Q 2025). Net loss: JP¥314.0m (loss widened 4.0% from 1Q 2025).
お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025
Reported Earnings • Jun 29Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
New Risk • Jun 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥6.62b market cap, or US$45.6m).
New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risk Market cap is less than US$100m (JP¥5.79b market cap, or US$40.3m).
Reported Earnings • May 11Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.
お知らせ • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.
お知らせ • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.
Reported Earnings • Feb 08Third quarter 2025 earnings released: JP¥0.63 loss per share (vs JP¥1.27 loss in 3Q 2024)Third quarter 2025 results: JP¥0.63 loss per share (improved from JP¥1.27 loss in 3Q 2024). Revenue: JP¥338.0m (up 207% from 3Q 2024). Net loss: JP¥172.0m (loss narrowed 38% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025
分析記事 • Jan 29We're Keeping An Eye On OncoTherapy Science's (TSE:4564) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024
分析記事 • Oct 11Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥9.81b market cap, or US$69.7m).
New Risk • Aug 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥562m revenue, or US$3.8m). Market cap is less than US$100m (JP¥12.9b market cap, or US$87.8m).
Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024
お知らせ • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.
分析記事 • Mar 01We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (JP¥8.68b market cap, or US$60.6m).
Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023
Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 07Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 24Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥124The company is down 2.0% from its price of JP¥126 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.